[1] Chistyakov DA,Savost' anov KV,Turakulov RI,et al.Genetic determinants of Graves disease[J].Mol Genet Metab,2000,71(1/2):66-69.
[2] 张珍,林益川,方志平,等.食盐加碘 10 年对地方性甲状腺肿和甲状腺功能亢进症患病率的影响[J].中华内分泌代谢杂志,2000,18(5):342-344.
[3] Jacobson EM,Tomer Y.The CD40,CTLA-4,thyroglobulin,TSH receptor,and PTPN22 gene quintet and its contribution to thyroidautoimmunity:back to the future[J].J Autoimmun,2007,28(2/3):85-98.
[4] Dechairo BM,Zabaneh D,Collins J,et al.Association of the TSHR gene with Graves' disease:the first disease specific locus[J].Eur J Hum Genet,2005,13(11):1223-1230.
[5] Frazier AL,Robbins LS,Stork PJ,et al.Isolation of TSH and LH/CG receptor cDNAs from human thyroid:regulation by tissue specific splicing[J].Mol Endocrinol,1990,4(8):1264-1276.
[6] Kakinuma A,Nagayama Y.Multiple messenger ribonucleic acid transcripts and revised gene organization of the human TSH receptor[J].Endocr J,2002,49(2):175-180.
[7] Hunt N,Willey KP,Abend N,et al.Novel splicing variants of the human thyrotropin receptor encode truncated polypeptides without a membrane-spanning domain[J].Endocrine,1995,3 ( 3 ):233-240.
[8] Rapoport B,Chazenbalk GD,Jaume JC,et al.The thyrotropin (TSH) receptor:interaction with TSH and autoantibodies[J].Endocr Rev,1998,19(6):673-716.
[9] Vassart G,Costagliola S.A physiological role for the posttranslational cleavage of the thyrotropin receptor[J].Endocrinology,2004,145(1):1-3.
[10] Ciullo I,Latif R,Graves P,et al.Functional assessment of the thyrotropin receptor-beta subunit [J].Endocrinology,2003,144(7):3176-3181.
[11] Chen CR,Pichurin P,Nagayama Y,et al.The thyrotropin receptor autoantigen in Graves disease is the culprit as well as the victim[J].J Clin Invest,2003,111(12):1897-1904.
[12] Pichurin PN,Chen CR,Chazenbalk GD,et al.Targeted expression of the human thyrotropin receptor A-subunit to the mouse thyroid:insight into overcoming the lack of response to A-subunit adenovirus immunization [J].J Immunol,2006,176 ( 1 ):668-676.
[13] Davies TF,Ando T,Lin RY,et al.Thyrotropin receptor-associated diseases:from adenomata to Graves disease[J].J Clin Invest,2005,115(8):1972-1983.
[14] Tonacchera M,Pinchera A.Thyrotrophin receptor polymorphisms and thyroid disease[J].J Clin Endocrinol Metab,2000,85(8):2637-2639.
[15] Dechairo BM,Zabaneh D,Collins J,et al.Association of the TSHR gene with Graves' disease:the first disease specific locus[J].Eur J Hum Genet,2005,13(11):1223-1230.
[16] Chistiakov DA,Savost' anov KV,Turakulov RI,et al.Further studies of genetic susceptibility to Graves' disease in a Russian population[J].Med Sci Monit,2002,8(3):CR180- CR184.
[17] Ban Y,Greenberg DA,Concepcion ES,et al.A germline single nucleotide polymorphism at the intracellular domain of the human thyrotropin receptor does not have a major effect on the development of Graves' disease[J].Thyroid,2002,12 (12):1079-1083.
[18] Burton PR,Clayton DG,Cardon LR,et al.Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants[J].Nat Genet,2007,39(11):1329-1337.
[19] Hiratani H,Bowden DW,Ikegami S,et al.Multiple SNPs in intron 7 of thyrotropin receptor are associated with Graves' disease[J].J Clin Endocrinol Metab,2005,90(5):2898-2903.
[20] Ho SC,Goh SS,Khoo DH.Association of Graves' disease with intragenic polymorphism of the thyrotropin receptor gene in a cohort of Singapore patients of multi-ethnic origins[J].Thyroid,2003,13(6):523-528.
[21] Yin X,Latif R,Bahn R,et al.Influence of the TSH receptor gene on susceptibility to Graves' disease and Graves' ophthalmopathy[J].Thyroid,2008,18(11):1201-1206.
[22] Brand OJ,Barrett JC,Simmonds MJ,et al.Association of the thyroid stimulating hormone receptor gene(TSHR) with Graves' disease[J].Hum Mol Genet,2009,18(9):1704-1713.
[23] Ploski R,Brand OJ,Jurecka-Lubieniecka B,et al.Thyroid stimulating hormone receptor(TSHR) intron 1 variants are major risk factors for Graves' disease in three European Caucasian cohorts[J].PLoS One,2010,5(11):e15512.
[24] 梁军,赵家军,高聆,等.TSH 受体基因 SNP 与 Graves 病、桥本甲状腺炎和结节性甲状腺肿之间的相关性研究[J].中华内分泌代谢杂志,2004,20(6):510-513.
[25] Gu LQ,Zhu W,Zhao SX,et al.Clinical associations of the genetic variants of CTLA-4,Tg,TSHR,PTPN22,PTPN12 and FCRL3 in patients with Graves' disease[J].Clin Endocrinol(Oxf),2010,72(2):248-255.
[26] Ye F,Hou P,Wu X,et al.The significance of immune-related molecule expression profiles in an animal model of Graves' disease[J].Autoimmunity,2011,45(2):143-152.
[27] Sibarani RP.Genetics of Graves' disease:the lost concept[J].Acta Med Indones,2009,41(1):37-40.
[28] Jeffreys J,Depraetere H,Sanders J,et al.Characterization of thyrotropin binding pocket [J].Thyroid,2002,12 ( 12 ):1051-1061.
[29] Wallaschofski H,Miehle K,Mayer A,et al.Prediction of remission or relapse for Graves' hyperthyroidism by the combined determination of stimulating,blocking and binding TSH-receptor antibodies after the withdrawal of antithyroid drug treatment[J].Horm Metab Res,2002,34(7):383-388.
[30] Wiersinga WM,Prummel MF.Pathogenesis of Graves'ophthalmopathy-current understanding[J].J Clin Endocrinol Metab,2000,86(2):501-503.
[31] Davies TF,Roti E,Braverman LE,et al.Thyroid controversy-stimulating antibodies[J].J Clin Endocrinol Metab,1998,83(11):3777-3785.
[32] Saravanan P,Dayan CM.Thyroid autoantibodies[J].Endocrinol Metab Clin North Am,2001,30(2):315-337.
[33] Menndez Torre E,Anda Apianiz E,Barberia Layana JJ,et al.Recurrence and prognostic factors after treatment with antithyroid agents in Graves-Basedow disease.Multicenter study in Northern Spain[J].Rev Clin Exp,2000,200(2):69-73.
[34] Metso S,Jaatinen P,Huhtala H,et al.Long-term follow-up study of radioiodine treatment of hyperthyroidism[J].Clin Endocrinol,2004,61(5):641-648.
[35] Cappelli C,Gandossi E,Castellano M,et al.Prognostic value of thyrotropin receptor antibodies ( TRAb) in Graves' disease:a 120 months prospective study[J].Endocr J,2007,54 (5 ):713-720.
[36] 缪婕,赵咏桔,王曙,等.Graves 病患者药物治疗复发的相关因素分析[J].中华内科杂志,2008,47(3):185-188.
[37] Chiapppori A,Villalta D,Bossert I,et al.Thyrotropin receptor autoantibody measurement following radiometabolic treatment of hyperthyroidism:comparison between different methods[J].J Endocrinol Invest,2010,33(3):197-201.
[38] Paunkovic J,Paunkovic N.Does autoantibody-negative Graves' disease exist? A second evaluation of the clinical diagnosis[J].Horm Metab Res,2006,38(1):53-56.
[39] Laurberg P,Bournaud C,Karmisholt J,et al.Management of Graves' hyperthyroidism in pregnancy:focus on both maternal and foetal thyroid function,and caution against surgical thyroidectomy in pregnancy[J].Eur J Endocrinol,2009,160(1):1-8.
[40] Laurberg P,Nygaard B,Glinoer D,et al.Guidelines for TSH-receptor antibody measurements in pregnancy:results of an evidence-based symposium organized by the European Thyroid Association[J].Eur J Endocrinol,1998,139(6):584-586.